

BIOMARIN PHARMACEUTICAL INC
 Form 4
 July 03, 2007

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Swidler Stuart J

(Last) (First) (Middle)

C/O BIOMARIN
 PHARMACEUTICAL INC., 105
 DIGITAL DRIVE

(Street)

NOVATO, CA 94949

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
 BIOMARIN PHARMACEUTICAL
 INC [BMRN]

3. Date of Earliest Transaction
 (Month/Day/Year)
 07/02/2007

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

___ Director ___ 10% Owner
 Officer (give title below) ___ Other (specify below)
 SVP, Clinical Affairs

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	Amount or Price			
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	M			12,500 A \$ 4	22,500	D	
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S			100 D \$ 18.12	22,400	D	
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S			1,150 D \$ 18.121	21,250	D	
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S			450 D \$ 18.131	20,800	D	
	07/02/2007 ⁽¹⁾	07/02/2007	S			300 D \$ 18.14	20,500	D	

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common Stock								
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	600	D	\$ 18.15	19,900	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	1,750	D	\$ 18.161	18,150	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	900	D	\$ 18.17	17,250	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	1,250	D	\$ 18.09	16,000	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	300	D	\$ 18.151	15,700	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	200	D	\$ 18.16	15,500	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	1,100	D	\$ 18.18	14,400	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	450	D	\$ 18.181	13,950	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	200	D	\$ 18.19	13,750	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	400	D	\$ 18.2	13,350	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	450	D	\$ 18.201	12,900	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	400	D	\$ 18.21	12,500	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	100	D	\$ 18.26	12,400	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	1,150	D	\$ 18.261	11,250	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	100	D	\$ 18.27	11,150	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	1,150	D	\$ 18.271	10,000	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

